Saffron

Saffron is one of the more credibly evidenced botanicals in the mood category, but it is a supplement for mild low mood, not a treatment for diagnosed depression. The trial base is real: small placebo-controlled RCTs from Akhondzadeh's group in Tehran in the mid-2000s, head-to-head comparisons against fluoxetine and imipramine showing roughly equivalent effects on Hamilton Depression Rating Scale scores in mild-to-moderate depression, and a Lopresti-led series of trials with the affron-branded extract in healthy adults with low mood, adolescents with subclinical anxiety and depression, and adults on antidepressants with residual symptoms.

The headline meta-analysis is Hausenblas 2013 in the Journal of Integrative Medicine, which pooled five RCTs and found a large effect size (Cohen's d ≈ 1.6) for saffron vs. placebo in major depressive disorder, with effects comparable to standard antidepressants in head-to-head trials. Lopresti and Drummond's 2014 systematic review in Human Psychopharmacology reached the same conclusion: large effects vs. placebo, similar effects vs. SSRIs. The honest caveats: most original trials came from a single Iranian research group, sample sizes were small (typically 30-40 per arm), and several of the affron-branded trials were funded by Pharmactive. None of that invalidates the signal, but it should keep expectations measured.

For low mood in non-clinical adults, the Kell 2017 placebo-controlled trial (n=128) used 28mg/day of affron over 4 weeks and found a significant drop in Profile of Mood States Total Mood Disturbance at the 28mg dose; a lower 22mg dose was not significantly different from placebo. Lopresti 2018 ran affron 28mg/day for 8 weeks in adolescents aged 12-16 with mild anxiety and depression and found roughly 33% reduction in internalizing symptoms by self-report vs. 17% on placebo (parent-rated outcomes were not significant - a real caveat). Lopresti 2019 tested affron as an add-on to existing antidepressant medication and found greater improvement on clinician-rated MADRS but not patient-rated MADRS-S, so the add-on case is mixed.

For PMS, Agha-Hosseini 2008 ran 30mg/day for two menstrual cycles in 50 women with regular cycles and PMS symptoms - 76% of saffron users had a ≥50% reduction in symptoms vs. 8% on placebo, with significant effects on both the daily symptom report and the Hamilton Depression scale. The effect size is large enough to take seriously despite the small sample.

For sleep, the more recent affron evening-dose trials have shown small but consistent improvements in sleep quality and sleep onset latency in adults with self-reported poor sleep, though the effects are smaller than what you would expect from a hypnotic.

For antidepressant-induced sexual dysfunction, two small placebo-controlled RCTs (Modabbernia 2012 in men, Kashani 2013 in women) found saffron 30mg/day improved IIEF erectile function scores and FSFI arousal and lubrication scores in patients stabilized on fluoxetine. These are interesting niche findings, not headline data.

For age-related macular degeneration, the Falsini and Marangoni group in Rome has run several small open-label and follow-up trials with 20mg/day saffron showing improvements in focal electroretinogram amplitude. Promising but mostly single-group, single-site, single-investigator.

Bottom line: a defensible choice for mild low mood, sleep, or PMS-related symptoms in adults who do not have a diagnosed mood or anxiety disorder. Anyone with diagnosed depression or anxiety should be working with a physician, and the SSRI/SNRI interaction is a real concern - the trials that added saffron to existing SSRIs did so under medical supervision, not as self-treatment.